Trial 0C-11-3

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Type: Cancer Therapy
Phase: Phase I/II
Status: Open to Accrual
Treatments: Anti-Angiogenesis
Randomized: No
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Anthony El-Khoueiry, M.D.
Other Trial Staff: Anayansi Miloud, D.M., Xiomara Menendez, R.N., Jubilee Acap, R.N., Jennifer Berg, D.M.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.